Eledon Pharmaceuticals - MarketMinute

Eledon Pharmaceuticals

Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern

San Diego, CA – November 10, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a dramatic collapse in its stock price, shedding nearly 50% of its value following the announcement of mixed results from its pivotal Phase 2 BESTOW clinical trial for tegoprubart. The drug, aimed at preventing organ rejection in kidney transplant

Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering

Eledon Pharmaceuticals (ELDN) Plummets Nearly 50% Amidst Mixed Phase 2 Trial Results, Sparking Investor Concern